Inversely to the efficacy evaluations, the safety analysis of CRS showed that the combination of anti-CD19/22 CAR T-cell therapy resulted in the least CRS event, which aligned with a previous meta-analysis [52]. This evidence concerns the gene CD19 and congenital rubella syndrome.